Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
57 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Apolipoprotein A I (APOA1) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Apolipoprotein A I (APOA1) - Pipeline Review, H2 2016', provides in depth analysis on Apolipoprotein A I (APOA1) targeted pipeline therapeutics. The report provides comprehensive information on the Apolipoprotein A I (APOA1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Apolipoprotein A I (APOA1) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Apolipoprotein A I (APOA1) - The report reviews Apolipoprotein A I (APOA1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Apolipoprotein A I (APOA1) targeted therapeutics and enlists all their major and minor projects - The report assesses Apolipoprotein A I (APOA1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Apolipoprotein A I (APOA1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Apolipoprotein A I (APOA1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Apolipoprotein A I (APOA1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Apolipoprotein A I (APOA1) Overview 6 Therapeutics Development 7 Apolipoprotein A I (APOA1) - Products under Development by Stage of Development 7 Apolipoprotein A I (APOA1) - Products under Development by Therapy Area 8 Apolipoprotein A I (APOA1) - Products under Development by Indication 9 Apolipoprotein A I (APOA1) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Apolipoprotein A I (APOA1) - Products under Development by Companies 12 Apolipoprotein A I (APOA1) - Products under Development by Universities/Institutes 14 Apolipoprotein A I (APOA1) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 19 Assessment by Molecule Type 21 Apolipoprotein A I (APOA1) - Companies Involved in Therapeutics Development 23 Arisaph Pharmaceuticals, Inc. 23 Cerenis Therapeutics Holding SA 24 CSL Limited 25 Esperion Therapeutics, Inc. 26 KineMed, Inc. 27 Apolipoprotein A I (APOA1) - Drug Profiles 28 4-WF - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 ARI-1778 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 CER-001 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 CER-522 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 CSL-112 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 D-4F - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 KM-011 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Apolipoprotein A I (APOA1) - Dormant Projects 39 Apolipoprotein A I (APOA1) - Discontinued Products 40 Apolipoprotein A I (APOA1) - Featured News & Press Releases 41 Sep 01, 2016: Positive safety and tolerability profile of CER-001 presented at the European Society of Cardiology Congress 2016 41 Aug 30, 2016: Completion of patient enrolment in the CARAT study - meeting the clinical schedule 41 Jun 02, 2016: Publication of the LOCATION Clinical Study Results in the Renowned Scientific Journal of the European Atherosclerosis Society (EAS) 43 Jan 28, 2016: Catalent Biologics And Cerenis Therapeutics Announce Phase III Trial Of CER-001 In Europe And North America Leveraging GPEx Cell Line Technology 44 Nov 10, 2015: Cerenis Therapeutics: New Data for CER-001 Presented in Key Oral Session at American Heart Association Conference 2015 45 Sep 08, 2015: First patients enter phase II CARAT trial to assess reduction in atherosclerotic plaque using CER-001 in post Acute Coronary Syndrome (ACS) patients 45 Jul 15, 2015: Cerenis Therapeutics Announces the Results of the LOCATION Study 46 Nov 18, 2014: CSL112 Found to Elevate Cholesterol Efflux in Patients with Coronary Artery Disease and Mechanism for Rapid Cholesterol Efflux Capacity Demonstrated 48 Nov 12, 2014: CSL Launches AEGIS-I, a Phase 2b Clinical Study of CSL112, a Novel Apolipoprotein A-I Infusion Therapy Designed to Rapidly Remove Cholesterol from Arteries and Stabilize Plaque 48 Sep 03, 2014: Cerenis Receives EMA Orphan Drug Designations for CER-001 for the Treatment of ApoA-I and ABCA-1 Deficiencies 49 Jun 02, 2014: Cerenis Reports Two Positive Phase II Studies for HDL Mimetic CER-001 at EAS 50 Jan 02, 2014: Cerenis Reports Top-Line Phase II Results for its HDL Mimetic CER-001 51 Nov 21, 2013: CSL releases positive data for potential new heart attack therapy and announces next phase of clinical development 52 Nov 05, 2012: Novel Apolipoprotein A-I Therapy, CSL112, May Represent New Option For Reducing Recurrent Heart Attack Risk, Early CSL Studies Show 53 Mar 15, 2011: Cerenis Initiates Phase II Study Of CER-001 In Acute Coronary Syndrome 55 Appendix 56 Methodology 56 Coverage 56 Secondary Research 56 Primary Research 56 Expert Panel Validation 56 Contact Us 56 Disclaimer 57
List of Tables
Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Early Stage Products, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Assessment by Monotherapy/Combination Products, H2 2016 16 Number of Products by Stage and Mechanism of Action, H2 2016 18 Number of Products by Stage and Route of Administration, H2 2016 20 Number of Products by Stage and Molecule Type, H2 2016 22 Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016 23 Pipeline by Cerenis Therapeutics Holding SA, H2 2016 24 Pipeline by CSL Limited, H2 2016 25 Pipeline by Esperion Therapeutics, Inc., H2 2016 26 Pipeline by KineMed, Inc., H2 2016 27 Dormant Projects, H2 2016 39 Discontinued Products, H2 2016 40
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
